Adults with asthma who inhale cannabis face significantly higher risks of severe respiratory episodes requiring medical intervention, challenging assumptions about marijuana's safety profile for those with existing lung conditions. This finding emerges from longitudinal tracking of nearly 4,500 participants, representing the largest population-level analysis of cannabis inhalation effects on asthma outcomes to date. The Population Assessment of Tobacco and Health study revealed that asthmatic adults who smoked combustible cannabis showed 64% higher odds of experiencing attacks requiring corticosteroid treatment within one year. Perhaps more surprisingly, those using electronic cannabis vaporizers—often marketed as safer alternatives—faced even greater risk with 81% higher odds of severe exacerbations. Both smoking and vaping patterns produced comparable elevation in attack frequency. These dose-response relationships suggest direct pulmonary irritation rather than coincidental associations. The respiratory impact contradicts popular beliefs about vaping's harm reduction potential, at least for vulnerable populations. While cannabis offers documented benefits for certain medical conditions, these findings highlight a critical blind spot in risk assessment. The study's strength lies in its nationally representative sample and longitudinal design, tracking actual health outcomes rather than relying on cross-sectional snapshots. However, the analysis cannot definitively establish causation, and individual variations in cannabis products, usage patterns, and asthma severity remain unexplored variables. For the estimated 25 million American adults with asthma, these results underscore the need for careful risk-benefit calculations when considering inhaled cannabis, regardless of delivery method.